Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FLIGHT Protocol: An Open Label Phase 1 Study Investigating the Effects of CDX-301 on the Safety, Clinical Activity, and Immune Priming of Glembatumumab Vedotin Combined with Pembrolizumab or Nivolumab in Unresectable or Metastatic Melanoma Patients Not Responding to the Anti-PD1 Therapy

Next Previous
X
Search
Trial Profile

FLIGHT Protocol: An Open Label Phase 1 Study Investigating the Effects of CDX-301 on the Safety, Clinical Activity, and Immune Priming of Glembatumumab Vedotin Combined with Pembrolizumab or Nivolumab in Unresectable or Metastatic Melanoma Patients Not Responding to the Anti-PD1 Therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 301 (Primary) ; Glembatumumab vedotin; Nivolumab; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms FLIGHT

    • Most Recent Events

    • 16 Jun 2021 Status changed from not yet recruiting to withdrawn prior to enrolment, because there was no significant advantage for use of study drug.
    • 14 Dec 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top